Novo Nordisk Announces US Launch of NovoFine® Plus, A New Needle for Patient with Diabetes

PLAINSBORO, N.J., Oct. 29, 2014 -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its shortest and thinnest pen needle, NovoFine® Plus, in the United States. NovoFine® Plus is a universal needle that works with all currently available insulin and some GLP-1 receptor agonist pens. The Food and Drug Administration (FDA) cleared the 510(k) application for NovoFine® Plus earlier this year.

NovoFine® Plus, which measures 32 gauge and 4 mm long, is one of the shortest, thinnest diabetes pen needles available today. Thinner needles are designed for less pain when injecting.[1] The new needle uses SuperFlowTM Technology, which is designed to enhance flow rate and reduce the dosage force when making the injection. The needle is also designed to resist bending or breaking.

"Novo Nordisk launched the world's first pen needle in 1985, and since then has strived to improve the injection experience for patients by developing smaller and thinner needles," said Camille Lee, senior vice president, diabetes marketing. "At the width of two human hairs, NovoFine® Plus is now our thinnest needle, and it features many improvements that are designed to cause less pain upon injection."

Pen needles are an integral part of the treatment experience for patients who rely on injectable therapies. Novo Nordisk is currently the only company that offers all components of the delivery system, with integrated development of insulin, needles, and pens. NovoFine®Plus joins an entire family of Novo Nordisk pen needles, including NovoTwist® 32G Tip, NovoFine® 32G Tip and NovoFine® Autocover®30G.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, visit novonordisk-us.comor follow our news in the U.S. on Twitter: @NovoNordiskUS.

Don't these look just like the BD Nano needles that have been out for a while?